Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

ABSTRACT: This work examines the skeletal accumulation of fluorescently tagged zoledronate in an animal model of chronic kidney disease. The results show higher accumulation in 24-h post-dose animals with lower kidney function due to greater amounts of binding at individual surfaces.

Introduction

Chronic kidney disease (CKD) patients suffer from increased rates of skeletal-related mortality from changes driven by biochemical abnormalities. Bisphosphonates are commonly used in reducing fracture risk in a variety of diseases, yet their use is not recommended in advanced stages of CKD. This study aimed to characterize the accumulation of a single dose of fluorescently tagged zoledronate (FAM-ZOL) in the setting of reduced kidney function.

Methods

At 25 weeks of age, FAM-ZOL was administer

SUBMITTER: Swallow EA 

PROVIDER: S-EPMC6103914 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature